WO2009078445A1 - 医薬品 - Google Patents

医薬品 Download PDF

Info

Publication number
WO2009078445A1
WO2009078445A1 PCT/JP2008/073000 JP2008073000W WO2009078445A1 WO 2009078445 A1 WO2009078445 A1 WO 2009078445A1 JP 2008073000 W JP2008073000 W JP 2008073000W WO 2009078445 A1 WO2009078445 A1 WO 2009078445A1
Authority
WO
WIPO (PCT)
Prior art keywords
homocysteic acid
pharmaceutical preparation
binding
syndrome
homocysteic
Prior art date
Application number
PCT/JP2008/073000
Other languages
English (en)
French (fr)
Inventor
Toru Hasegawa
Kohji Mizuno
Naoto Matsuyama
Original Assignee
Alfresa Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfresa Pharma Corporation filed Critical Alfresa Pharma Corporation
Publication of WO2009078445A1 publication Critical patent/WO2009078445A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

【課題】ホモシステイン酸がNMDA受容体に結合するのを阻害すると共に、細胞内のホモシステイン酸濃度の上昇を抑制し、しかも、神経変性疾患や、心臓病、ストレス症候群、不安症候群、骨粗鬆症の予防や改善、治療を行うことのできる医薬品を提供する。 【解決手段】本発明に係る医薬品では、抗ホモシステイン酸抗体またはその抗原結合フラグメントを有効成分として含有することとした。また、所定の担体にホモシステイン酸、又は薬学的に許容しうる範囲のホモシステイン酸塩若しくはホモシステイン酸誘導体を結合した複合体を含有することとした。
PCT/JP2008/073000 2007-12-17 2008-12-17 医薬品 WO2009078445A1 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007-325200 2007-12-17
JP2007325200 2007-12-17
JP2008130024 2008-05-16
JP2008-130024 2008-05-16
JP2008233985 2008-09-11
JP2008-233985 2008-09-11

Publications (1)

Publication Number Publication Date
WO2009078445A1 true WO2009078445A1 (ja) 2009-06-25

Family

ID=40795558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/073000 WO2009078445A1 (ja) 2007-12-17 2008-12-17 医薬品

Country Status (1)

Country Link
WO (1) WO2009078445A1 (ja)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535289A (ja) * 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン 神経疾患のワクチン媒介治療
JP2005082523A (ja) * 2003-09-08 2005-03-31 Toru Hasegawa 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
WO2007116458A1 (ja) * 2006-03-30 2007-10-18 Tohru Hasegawa 神経変性疾患治療薬

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535289A (ja) * 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン 神経疾患のワクチン媒介治療
JP2005082523A (ja) * 2003-09-08 2005-03-31 Toru Hasegawa 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
WO2007116458A1 (ja) * 2006-03-30 2007-10-18 Tohru Hasegawa 神経変性疾患治療薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Characterization of monoclonal antibody to L-homocysteic acid and its immunohistochemistry in rat hippocampus", JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, MEDICAL SCIENCES, vol. 25, no. 1, 2005, pages 1 - 4 *
DATABASE CAPLUS LIU, CHANGJIN ET AL: "Liangpin, Preparation and characterization of monoclonal antibody to L- homocysteic acid", Database accession no. 2001:894214 *
TONGJI YIKE DAXUE XUEBAO, vol. 30, no. 5, 2001, pages 410 - 412 *

Similar Documents

Publication Publication Date Title
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
HK1131790A1 (en) High affinity human antibodies to human il-4 receptor
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2008050329A3 (en) Novel sirnas and methods of use thereof
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
TW200621690A (en) Novel compounds
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2009022354A3 (en) Modified dosage forms of tacrolimus
WO2011090270A3 (ko) 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물
WO2013055684A8 (en) Rasagiline citramide
WO2007038506A3 (en) Method for the treatment of cachexia
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2012010966A3 (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
SG171601A1 (en) Further medical uses of antisecretory protein
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2009080764A3 (en) Oral or nasal administration of compounds comprising amino acid sequences
WO2008049990A3 (fr) Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
MX2008013777A (es) Usos medicos adicionales de la proteina antisecretora.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08862557

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08862557

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP